Christine Brase
Wuppertal, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian.
Journal: Clinical pharmacokinetics
Published: September 29, 2024
Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data.
Journal: Clinical and translational science
Published: April 03, 2024
Pharmacokinetics of asundexian with combined CYP3A and P-gp inhibitors and an inducer: Target in vitro and in vivo studies.
Journal: British journal of clinical pharmacology
Published: September 01, 2023
Assessment of the CYP3A4 Induction Potential by Carbamazepine: Insights from Two Clinical DDI Studies and PBPK Modeling.
Journal: Clinical pharmacology and therapeutics
Published: August 17, 2023
No Influence of Asundexian on Cardiac Repolarization.
Journal: Clinical pharmacology in drug development
Published: August 09, 2023
Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor Asundexian in Rats and in Humans.
Journal: European journal of drug metabolism and pharmacokinetics
Published: June 06, 2023
Effects of Tablet Formulation, Food, or Gastric pH on the Bioavailability of Asundexian.
Journal: Clinical pharmacology in drug development
Published: July 20, 2022
Thrombus formation at the MitraClip system during percutaneous mitral valve repair.
Journal: JACC. Cardiovascular interventions
Published: February 24, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026